肝硬化中的他汀类药物：希望还是炒作？
Statins in Cirrhosis: Hope or Hype?
作者信息
Shaffer Lauren R, Mahmud Nadim
机构信息
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
出版信息
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1032-1046. doi: 10.1016/j.jceh.2023.05.002. Epub 2023 May 12.
In recent years, studies have demonstrated the benefits of statins in a range of chronic diseases separate from cardiovascular outcomes. Early studies in the context of chronic liver disease have suggested favorable effects of statins leading to slowed fibrosis progression, reduced portal pressures, decreased rates of hepatic decompensation, and improved survival. This has increased interest in the potential role that statins may have in the management of chronic liver disease and cirrhosis, though many questions remain unanswered, including concerns regarding the safety of higher dose statins in patients with advanced decompensated cirrhosis. In this review, we provide an update on the current literature addressing the use of statins in patients with cirrhosis and highlight areas in which additional studies are needed.
近年来，研究表明他汀类药物在一系列与心血管结局无关的慢性疾病中具有益处。早期在慢性肝病背景下的研究表明，他汀类药物具有有益作用，可导致纤维化进展减缓、门静脉压力降低、肝失代偿率下降以及生存率提高。这增加了人们对他汀类药物在慢性肝病和肝硬化管理中可能发挥的潜在作用的兴趣，尽管许多问题仍未得到解答，包括对晚期失代偿性肝硬化患者使用高剂量他汀类药物安全性的担忧。在本综述中，我们提供了关于目前探讨他汀类药物在肝硬化患者中应用的文献的最新情况，并强调了需要进一步研究的领域。
Zotero 插件